Matches in Nanopublications for { <http://bio2rdf.org/drugbank:DB05773> ?p ?o ?g. }
Showing items 1 to 24 of
24
with 100 items per page.
- drugbank:DB05773 type drugbank_vocabulary:Drug assertion.
- drugbank:DB05773 label "ado-trastuzumab emtansine [drugbank:DB05773]" assertion.
- drugbank:DB05773 seeAlso DB05773 assertion.
- drugbank:DB05773 seeAlso ado-trastuzumab-emtansine.html assertion.
- drugbank:DB05773 seeAlso kadcyla-drug.htm assertion.
- drugbank:DB05773 identifier "drugbank:DB05773" assertion.
- drugbank:DB05773 description "Ado-trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) as an investigational drug, is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent, DM1. T-DM1 combines two strategies-- anti-HER2 activity and targeted intracellular delivery of the potent anti-microtubule agent, DM1 (a maytansine derivative)--to produce cell cycle arrest and apoptosis. Ado-trastuzumab emtansine is marketed under the brand name Kadcyla and is indicated for use in HER2-positive, metastatic breast cancer patients who have already used taxane and/or trastuzumab for metastatic disease or had their cancer recur within 6 months of adjuvant treatment. The FDA label has two precautions. First that ado-trastuzumab emtansine and trastuzumab cannot be interchanged. Second that there is a black box warning of serious side effects such as hepatotoxicity, embryo-fetal toxicity, and cardiac toxicity." assertion.
- drugbank:DB05773 title "ado-trastuzumab emtansine" assertion.
- drugbank:DB05773 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00363_DB05773 assertion.
- drugbank:DB05773 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB05773_DB08879 assertion.
- drugbank:DB05773 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00252_DB05773 assertion.
- drugbank:DB05773 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00337_DB05773 assertion.
- drugbank:DB05773 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB05773_DB08895 assertion.
- drugbank:DB05773 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00108_DB05773 assertion.
- drugbank:DB05773 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00864_DB05773 assertion.
- drugbank:DB05773 bio2rdf_vocabulary:identifier "DB05773" assertion.
- drugbank:DB05773 bio2rdf_vocabulary:namespace "drugbank" assertion.
- drugbank:DB05773 bio2rdf_vocabulary:uri "http://bio2rdf.org/drugbank:DB05773" assertion.
- drugbank:DB05773 bio2rdf_vocabulary:x-identifiers.org DB05773 assertion.
- drugbank:DB05773 drugbank_vocabulary:drugbank-id "DB05773" assertion.
- drugbank:DB05773 drugbank_vocabulary:x-cas cas:1018448-65-1 assertion.
- drugbank:DB05773 drugbank_vocabulary:x-kegg kegg:D09980 assertion.
- drugbank:DB05773 drugbank_vocabulary:x-wikipedia wikipedia:Trastuzumab_emtansine assertion.
- drugbank:DB05773 drugbank_vocabulary:x-ndc ndc:50242-087-01 assertion.